Xeris Q3 Revenue Jumps 44% to $107M; 2026 Guidance Raised, 2030 Target Lifted to $1B+
XERS has more than doubled off its 52-week low of $5.25.
Summary
Xeris reported Q3 2026 revenue of $107.2 million, up 44%, with Recorlev up 93% to $71.5 million and net income of $11.3 million. It raised 2026 revenue guidance to $395–405 million and its 2030 outlook to more than $1 billion.
Key Events · Earnings and Guidance · XERS
-
Q3 Revenue Up 44% to $107.2M
Total revenue rose to $107.2 million from $74.4 million a year earlier, driven by Recorlev net revenue of $71.5 million, up 93% from $37.0 million.
-
Swing to $11.3M Quarterly Profit
Net income was $11.3 million versus $0.6 million in Q3 2025; Adjusted EBITDA reached $30.8 million, an improvement of $13.3 million, and gross margin rose to 88% from 85%.
-
2026 Guidance Raised to $395–405M
Full-year 2026 total revenue guidance was raised to $395–405 million, against $282.5 million booked in the first nine months of 2026.
-
2030 Outlook Lifted to $1B+
The 2030 total revenue outlook was raised to more than $1 billion from approximately $750 million, with Recorlev seen approaching $1 billion in annual net revenue three to four years sooner than previously expected.
Analysis · XERS · Life Sciences
Xeris swung to an $11.3 million quarterly profit from a $0.6 million profit a year earlier, and the growth is concentrated where it matters: Recorlev revenue nearly doubled to $71.5 million as the expanded commercial team converted into prescriptions. Management raised full-year 2026 revenue guidance to $395–405 million and pulled forward its 2030 target to more than $1 billion from roughly $750 million — a much bigger revision than a typical quarterly tweak, and it implies Recorlev alone approaches $1 billion annually three to four years sooner than previously expected. The one blemish is Gvoke, down 14% to $21.7 million on a one-time $4 million gross-to-net adjustment, and SG&A rose 38% to fund the Recorlev build. With $131.1 million of cash and the 2028 convertible notes fully retired in July, the balance sheet no longer forces a financing decision.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XERS was trading at $11.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $5.25 to $11.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.